Takeda's Deal Flurry Set To Wane
Takeda's reorganization and the focusing of its R&D on specialty medicines in three sectors is shifting to the next stage, with products moving through its pipeline; the company has lifted its financial outlook at the six-month stage, but is wary of the emergence of US generic competition to Velcade later this year.
You may also be interested in...
While Takeda has admitted it is considering a possible offer for Shire, any deal would seem to go against some of the past strategy signals from the Japanese company, suggesting the availability of an increasingly rare acquisition target may be more of a key consideration.
A new UK company set up by entrepreneur Bryan Morton to develop an innovative medicine for ankylosing spondylitis may be an example of how start-up companies could be supported through the UK's just announced industrial strategy for the life sciences sector.
China FDA greenlights Lundbeck's Brintellix for severe depression, and more new drug approvals may be on the way. Physician education will be key for Brintellix, given relatively low number of psychiatrists in China.